Verrica Pharmaceuticals Announces Second Amendment To Its Existing Collaboration And Licensing Agreement With Torii Pharmaceutical To Initiate A Global Pivotal Phase 3 Trial Of Verrica's Ycanth For Common Warts

Author: Benzinga Newsdesk | July 01, 2025 06:06am

• Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule.
• Verrica to receive a $10 million milestone payment from Torii in cash upon the approval of YCANTH® (TO-208 in Japan) for molluscum contagiosum in Japan; approval decision expected by the end of 2025.
• Torii to fund the first $40 million of out-of-pocket costs for the global study, representing approximately 90% of the current clinical budget.
• Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for this multi-billion dollar addressable market.
• Company expects to dose first patient in the Phase 3 trial in the United States in the fourth quarter of 2025.
• Verrica to maintain ownership of global rights to YCANTH for all indications in all territories outside of Japan

Posted In: VRCA